Cargando…

Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia

Detalles Bibliográficos
Autores principales:	Biolato, Marco, Vitale, Federica, Marrone, Giuseppe, Miele, Luca, Grieco, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632300/ https://www.ncbi.nlm.nih.gov/pubmed/36340807 http://dx.doi.org/10.1093/gastro/goac059

Ejemplares similares

A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series
por: Biolato, Marco, et al.
Publicado: (2022)

Correction to: Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia
Publicado: (2022)

Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines
por: Biolato, Marco, et al.
Publicado: (2023)

Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties
por: Marrone, Giuseppe, et al.
Publicado: (2023)

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach
por: Biolato, Marco, et al.
Publicado: (2017)

Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation
por: Biolato, Marco, et al.
Publicado: (2021)

Correction to: Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure
por: Satapathy, Sanjaya K., et al.
Publicado: (2023)

Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
por: Mladsi, Deirdre, et al.
Publicado: (2020)

Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges
por: Huang, Ao, et al.
Publicado: (2022)

Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
por: Abdelsamia, Mahmoud, et al.
Publicado: (2023)

Gallbladder perforation without cholecystitis in a patient awaiting liver transplantation: a peculiar case report of anaemia in cirrhosis
por: Biolato, Marco, et al.
Publicado: (2019)

Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation
por: Nicoletti, Alberto, et al.
Publicado: (2019)

Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation
por: Zhou, Meng, et al.
Publicado: (2022)

Disseminated intravascular coagulation after splenic artery aneurysm coils embolization: an unexpected surprise
por: Biolato, Marco, et al.
Publicado: (2023)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis
por: Lu, Jun, et al.
Publicado: (2022)

Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study
por: Wang, Yong-Shuai, et al.
Publicado: (2022)

Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease
por: Biolato, Marco, et al.
Publicado: (2019)

Procedure‐related bleeding risk in patients with cirrhosis and severe thrombocytopenia
por: Alvaro, Domenico, et al.
Publicado: (2021)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study
por: Oladapo, Abiola, et al.
Publicado: (2023)

Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China
por: Mei, Heng, et al.
Publicado: (2023)

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
por: Aiello, Andrea, et al.
Publicado: (2023)

Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?
por: Biolato, Marco, et al.
Publicado: (2022)

Efficacy and safety of avatrombopag in aplastic anemia patients with liver disease
por: Wang, Huaquan, et al.
Publicado: (2023)

Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Chunlu, et al.
Publicado: (2019)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

Correlation of the transaminases alteration with the clinical severity of patients with COVID- 19: A meta-analysis of the first global outbreak
por: Miele, L., et al.
Publicado: (2021)

A Role for the Biological Clock in Liver Cancer
por: Mazzoccoli, Gianluigi, et al.
Publicado: (2019)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis
por: Wojciechowski, Piotr, et al.
Publicado: (2021)

Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Zhu, Lidan, et al.
Publicado: (2022)

Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study
por: Ruan, Yongsheng, et al.
Publicado: (2023)

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies
por: Poordad, Fred, et al.
Publicado: (2020)

Acute liver failure in Still’s disease relapse during pregnancy: case report and discussion of a possible trigger role of DILI
por: Marrone, Giuseppe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nedsgg2hjl5lmi4cct2vsfvnk4